脂蛋白(a)、氧化磷脂与冠心病严重程度及结局
在CASABLANCA研究1098例接受冠状动脉造影的患者中,Lp(a)与OxPL-apoB与多支冠状动脉病变相关,Lp(a)、OxPL-apoB和OxPL-apo(a)均与随访期主要不良心血管事件相关。
要点
- Lp(a)与OxPL-apoB与多支冠状动脉病变风险独立相关。
- Lp(a)、OxPL-apoB和OxPL-apo(a)均与随访期MACE风险相关。
- Lp(a)与OxPL-apoB、OxPL-apo(a)高度相关(Spearman R≥0.91)。
核心结论
- 在接受冠状动脉造影的患者中,Lp(a)和OxPL-apoB与多支冠状动脉病变相关。
- Lp(a)、OxPL-apoB和OxPL-apo(a)均与随访期新发心血管事件相关。
研究设计与样本
- CASABLANCA研究(NCT00842868)纳入1098例接受冠状动脉造影的参与者,测量Lp(a)、OxPL-apoB和OxPL-apo(a)。
- 采用逻辑回归评估多支冠状动脉狭窄风险,采用Cox比例风险回归评估MACE风险。
主要发现
- Lp(a)中位数为26.45 nmol/L(IQR:11.39-89.49 nmol/L)。
- Lp(a)、OxPL-apoB和OxPL-apo(a)两两高度相关(Spearman R≥0.91)。
- Lp(a)每倍增与多支CAD的OR为1.10(95%CI:1.03-1.18;P=0.006),OxPL-apoB每倍增OR为1.18(95%CI:1.03-1.34;P=0.01),OxPL-apo(a)每倍增OR为1.07(95%CI:0.99-1.16;P=0.07)。
- Lp(a)每倍增与MACE的HR为1.08(95%CI:1.03-1.14;P=0.001),OxPL-apoB每倍增HR为1.15(95%CI:1.05-1.26;P=0.004),OxPL-apo(a)每倍增HR为1.07(95%CI:1.01-1.14;P=0.02)。
临床怎么用
- 对接受冠状动脉造影的患者,可关注Lp(a)和OxPL-apoB水平以评估多支冠状动脉病变风险。
- Lp(a)相关生物标志物有助于识别随访期MACE高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lipoprotein(a) (Lp[a]) and oxidized phospholipids (OxPLs) are each independent risk factors for atherosclerotic cardiovascular disease. The extent to which Lp(a) and OxPLs predict coronary artery disease (CAD) severity and outcomes in a contemporary, statin-treated cohort is not well established. OBJECTIVES: This study sought to evaluate the relationships between Lp(a) particle concentration and OxPLs associated with apolipoprotein B (OxPL-apoB) or apolipoprotein(a) (OxPL-apo[a]) with angiographic CAD and cardiovascular outcomes. METHODS: Among 1,098 participants referred for coronary angiography in the CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular Diseases) study, Lp(a), OxPL-apoB, and OxPL-apo(a) were measured. Logistic regression estimated the risk of multivessel coronary stenoses by Lp(a)-related biomarker level. Cox proportional hazards regression estimated the risk of major adverse cardiovascular events (MACEs) (coronary revascularization, nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death) in follow-up. RESULTS: Median Lp(a) was 26.45 nmol/L (IQR: 11.39-89.49 nmol/L). Lp(a), OxPL-apoB, and OxPL-apo(a) were highly correlated (Spearman R ≥0.91 for all pairwise combinations). Lp(a) and OxPL-apoB were associated with multivessel CAD. Odds of multivessel CAD per doubling of Lp(a), OxPL-apoB, and OxPL-apo(a) were 1.10 (95% CI: 1.03-1.18; P = 0.006), 1.18 (95% CI: 1.03-1.34; P = 0.01), and 1.07 (95% CI: 0.99-1.16; P = 0.07), respectively. All biomarkers were associated with cardiovascular events. HRs for MACE per doubling of Lp(a), OxPL-apoB, and OxPL-apo(a) were 1.08 (95% CI: 1.03-1.14; P = 0.001), 1.15 (95% CI: 1.05-1.26; P = 0.004), and 1.07 (95% CI: 1.01-1.14; P = 0.02), respectively. CONCLUSIONS: In patients undergoing coronary angiography, Lp(a) and OxPL-apoB are associated with multivessel CAD. Lp(a), OxPL-apoB, and OxPL-apo(a) are associated with incident cardiovascular events. (Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA]; NCT00842868).
引用
- Gilliland TC, Liu Y, Mohebi R, et al. Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes. J Am Coll Cardiol. 2023. PMID: 37137588. doi:10.1016/j.jacc.2023.02.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。